{"version":"1.0","type":"rich","width":"560px","height":"140px","title":"Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4\/EMN30 Trial","url":"https:\/\/www.myelomasociety.org\/phase-3-study-of-teclistamab-tec-in-combination-with-lenalidomide-len-and-tec-alone-versus-len-alone-in-newly-diagnosed-multiple-myeloma-ndmm-as-maintenance-therapy-following-autologous-stem-cel\/","author_name":"IMSound","author_url":"https:\/\/www.myelomasociety.org","thumbnail_url":"https:\/\/www.myelomasociety.org\/wp-content\/uploads\/2024\/07\/IMSound-Logo-only-v2.png","html":"<iframe width=\"560px\" height=\"140px\" src=\"https:\/\/www.myelomasociety.org\/phase-3-study-of-teclistamab-tec-in-combination-with-lenalidomide-len-and-tec-alone-versus-len-alone-in-newly-diagnosed-multiple-myeloma-ndmm-as-maintenance-therapy-following-autologous-stem-cel\/?standalonePlayer\"><\/iframe>"}